CORD-19:038354e8830fe01feb621a12e8a8c467a15b6354 / 23455-23628 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T139","span":{"begin":0,"end":173},"obj":"Sentence"},{"id":"T1501","span":{"begin":0,"end":173},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Affected patients surviving severe disease may have chronic sequelae in the form of bronchiectasis, bronchiolitis obliterans and hyperlucent lung (Murtagh and Kajon, 1997) ."}

{"project":"Epistemic_Statements","denotations":[{"id":"T47","span":{"begin":0,"end":173},"obj":"Epistemic_statement"}],"text":"Affected patients surviving severe disease may have chronic sequelae in the form of bronchiectasis, bronchiolitis obliterans and hyperlucent lung (Murtagh and Kajon, 1997) ."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T139","span":{"begin":0,"end":173},"obj":"Sentence"}],"text":"Affected patients surviving severe disease may have chronic sequelae in the form of bronchiectasis, bronchiolitis obliterans and hyperlucent lung (Murtagh and Kajon, 1997) ."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T161","span":{"begin":84,"end":98},"obj":"Disease"},{"id":"T162","span":{"begin":100,"end":124},"obj":"Disease"},{"id":"T163","span":{"begin":100,"end":113},"obj":"Disease"},{"id":"T164","span":{"begin":129,"end":145},"obj":"Disease"}],"attributes":[{"id":"A161","pred":"mondo_id","subj":"T161","obj":"http://purl.obolibrary.org/obo/MONDO_0004822"},{"id":"A162","pred":"mondo_id","subj":"T162","obj":"http://purl.obolibrary.org/obo/MONDO_0015265"},{"id":"A163","pred":"mondo_id","subj":"T163","obj":"http://purl.obolibrary.org/obo/MONDO_0002465"},{"id":"A164","pred":"mondo_id","subj":"T164","obj":"http://purl.obolibrary.org/obo/MONDO_0000925"}],"text":"Affected patients surviving severe disease may have chronic sequelae in the form of bronchiectasis, bronchiolitis obliterans and hyperlucent lung (Murtagh and Kajon, 1997) ."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T34","span":{"begin":84,"end":98},"obj":"Phenotype"},{"id":"T35","span":{"begin":100,"end":124},"obj":"Phenotype"}],"attributes":[{"id":"A34","pred":"hp_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/HP_0002110"},{"id":"A35","pred":"hp_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/HP_0011946"}],"text":"Affected patients surviving severe disease may have chronic sequelae in the form of bronchiectasis, bronchiolitis obliterans and hyperlucent lung (Murtagh and Kajon, 1997) ."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T18","span":{"begin":141,"end":145},"obj":"Body_part"}],"attributes":[{"id":"A18","pred":"uberon_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Affected patients surviving severe disease may have chronic sequelae in the form of bronchiectasis, bronchiolitis obliterans and hyperlucent lung (Murtagh and Kajon, 1997) ."}